Showing results (91-100 of 98) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Antimicrobial Agents and Chemotherapy|February 13, 2001
Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy malesR E Polk, D F Brophy, D S Israel, et al.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|February 1, 1995
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virusS H Cheeseman, D Havlir, M M McLaughlin, et al.Journal of Clinical Pharmacology|April 18, 2001
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjectsB M Sadler, G E Chittick, R E Polk, et al.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1996
Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol TeamR T Schooley, T B Campbell, D R Kuritzkes, et al.The New England Journal of Medicine|October 10, 1996
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDSL D Saravolatz, D L Winslow, G Collins, et al.The New England Journal of Medicine|August 17, 1995
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials GroupP A Volberding, S W Lagakos, J M Grimes, et al.JAMA|August 10, 1994
The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials GroupP A Volberding, S W Lagakos, J M Grimes, et al.Journal of Clinical Pharmacology|July 1, 1997
Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipientsS A Gruber, M Gallichio, T G Rosano, et al.Pageof 10